Cargando…

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Gonçalves, Joao, Hickling, Timothy P., Jones, Heather E., Marshall, Lisa, Isaacs, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113198/ https://www.ncbi.nlm.nih.gov/pubmed/32103456 http://dx.doi.org/10.1007/s40259-020-00410-5

Ejemplares similares

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
por: Strand, Vibeke, et al.
Publicado: (2019)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Biologics and Biosimilars in Psoriasis
por: Ahmed, Sk Shahriar, et al.
Publicado: (2023)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)

Insights on the use of biosimilars in the treatment of inflammatory bowel disease
por: Zheng, Michael K, et al.
Publicado: (2017)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019)

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council
por: Cohen, Arnon D., et al.
Publicado: (2020)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
por: Strand, Vibeke, et al.
Publicado: (2017)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
por: Fischer, Sarah, et al.
Publicado: (2021)

Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
por: Hakizimana, Ali, et al.
Publicado: (2017)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience
por: Chopra, Ajay, et al.
Publicado: (2020)

Biosimilars in inflammatory bowel disease: A review of post-marketing experience
por: Deiana, Simona, et al.
Publicado: (2017)

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
por: Park, Sang Hyoung, et al.
Publicado: (2020)

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients
por: Garcia, Karoline Soares, et al.
Publicado: (2021)

Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
por: Najeeb, Hala, et al.
Publicado: (2022)

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease
por: Shenoy, Padmanabha, et al.
Publicado: (2021)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Guselkumab for plaque psoriasis
Publicado: (2019)

Bimekizumab for plaque psoriasis
Publicado: (2022)

Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model
por: Kvist, Peter H, et al.
Publicado: (2009)

The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence
por: Zhang, Mengyuan, et al.
Publicado: (2021)

Imbalanced machine learning classification models for removal biosimilar drugs and increased activity in patients with rheumatic diseases
por: Castro Corredor, David, et al.
Publicado: (2023)

Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program “Treatment of moderate and severe forms of plaque psoriasis (B.47)” of the National Health Fund in Poland
por: Owczarek, Witold, et al.
Publicado: (2021)

Regulatory B cells in autoimmune rheumatic diseases
por: Sakkas, Lazaros I.
Publicado: (2017)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
por: Rawla, Prashanth, et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n0mlbnvs8npb1h9n5q0cb6doko